Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Want to see AU:PIQ full AI Analyst Report?
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.12 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$20.65M
Enterprise ValueAU$15.31M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,197,510
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Bulls Say, Bears Say
Bulls Say
Proteomics-focused DiagnosticsA focused proteomics diagnostic platform is a durable strategic advantage: specialized biomarker tests can create high barriers to entry, enable differentiated clinical utility, and support long-term licensing or adoption opportunities in precision diagnostics if regulatory and reimbursement progress occurs.
Two Complementary Revenue StreamsHaving both diagnostics and fee-for-service laboratory services diversifies revenue sources. Services can provide steady project cash flow and maintain lab utilization while diagnostics scale through commercialization, reducing single-stream dependence and smoothing revenue over time.
Very Low Financial LeverageMinimal leverage gives the company financial flexibility and lower interest burden, preserving balance-sheet capacity to raise capital or invest in commercialization. This structural cushion improves resilience against cyclical downturns and supports runway while margins recover.
Bears Say
Severe Revenue ContractionA ~72% revenue drop is a material structural issue: loss of scale undermines operating leverage, reduces resources for R&D and commercialization, and may reflect weakened market adoption or lost contracts, making sustainable recovery and profitable scaling more difficult.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows erode liquidity and force reliance on external funding or equity dilution. This constrains the company's ability to invest in regulatory, commercial rollouts and maintain lab capacity until unit margins or volumes improve.
Ongoing Losses / Negative MarginsSustained negative EBIT and net margins indicate operations don't cover costs at current scale. Continued losses deplete equity, limit reinvestment capacity, and make it harder to demonstrate profitability to partners or payors—critical for long-term commercial adoption.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.12 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$20.65M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 82 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,197,510 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
-93.66%
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Limited is a medical technology firm deeply engaged in the field of proteomics. Its core offering is PromarkerD, an advanced predictive test for diabetic kidney disease. Additionally, the company is diligently working on developing new diagnostic tools for conditions such as endometriosis and giardia. Beyond its product line, the firm also provides specialized analytical services, particularly focusing on contract research. Proteomics International Laboratories Limited maintains significant research collaborations: it partners with the Busselton Population Medical Research Institute and Janssen Research & Development to explore treatments for diabetic kidney disease, and also collaborates with the QIMR Berghofer Medical Research Institute on initiatives aimed at detecting oesophageal adenocarcinoma. Established in 2001, the company's operations are headquartered in Perth, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Pharmaust Limited
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---